TY - JOUR
T1 - Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα
AU - Radomska, Hanna S.
AU - Alberich-Jordà, Meritxell
AU - Will, Britta
AU - Gonzalez, David
AU - Delwel, Ruud
AU - Tenen, Daniel G.
PY - 2012/8/1
Y1 - 2012/8/1
N2 - Mutations that activate the fms-like tyrosine kinase 3 (FLT3) receptor are among the most prevalent mutations in acute myeloid leukemias. The oncogenic role of FLT3 mutants has been attributed to the abnormal activation of several downstream signaling pathways, such as STAT3, STAT5, ERK1/2, and AKT. Here, we discovered that the cyclin-dependent kinase 1 (CDK1) pathway is also affected by internal tandem duplication mutations in FLT3. Moreover, we also identified C/EBPα, a granulopoiesis-promoting transcription factor, as a substrate for CDK1. We further demonstrated that CDK1 phosphorylates C/EBPα on serine 21, which inhibits its differentiation-inducing function. Importantly, we found that inhibition of CDK1 activity relieves the differentiation block in cell lines with mutated FLT3 as well as in primary patient-derived peripheral blood samples. Clinical trials with CDK1 inhibitors are currently under way for various malignancies. Our data strongly suggest that targeting the CDK1 pathway might be applied in the treatment of FLT3ITD mutant leukemias, especially those resistant to FLT3 inhibitor therapies.
AB - Mutations that activate the fms-like tyrosine kinase 3 (FLT3) receptor are among the most prevalent mutations in acute myeloid leukemias. The oncogenic role of FLT3 mutants has been attributed to the abnormal activation of several downstream signaling pathways, such as STAT3, STAT5, ERK1/2, and AKT. Here, we discovered that the cyclin-dependent kinase 1 (CDK1) pathway is also affected by internal tandem duplication mutations in FLT3. Moreover, we also identified C/EBPα, a granulopoiesis-promoting transcription factor, as a substrate for CDK1. We further demonstrated that CDK1 phosphorylates C/EBPα on serine 21, which inhibits its differentiation-inducing function. Importantly, we found that inhibition of CDK1 activity relieves the differentiation block in cell lines with mutated FLT3 as well as in primary patient-derived peripheral blood samples. Clinical trials with CDK1 inhibitors are currently under way for various malignancies. Our data strongly suggest that targeting the CDK1 pathway might be applied in the treatment of FLT3ITD mutant leukemias, especially those resistant to FLT3 inhibitor therapies.
UR - http://www.scopus.com/inward/record.url?scp=84864742952&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864742952&partnerID=8YFLogxK
U2 - 10.1172/JCI43354
DO - 10.1172/JCI43354
M3 - Article
C2 - 22797303
AN - SCOPUS:84864742952
SN - 0021-9738
VL - 122
SP - 2955
EP - 2966
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 8
ER -